Q-omics provides the consensus-scored CORO1B profile across patient tissues and cancer cell-line models. CORO1B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CORO1B is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, CORO1B protein abundance shows 19,361 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, KIRP, and PDAC as cancer lineages where CORO1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO1B survival associations across molecular data types. CORO1B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO1B RNA expression–survival associations across cancer types. High CORO1B expression shows unfavorable associations in ACC, READ, LIHC, LGG and KIRC, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for CORO1B RNA expression.
This table summarizes CORO1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CORO1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO1B shows higher tumor expression in KIRP, LIHC, KIRC, HNSC, BLCA and LUAD. The KIRP box plot shows higher CORO1B RNA expression in tumor versus normal tissue (log2 FC = +0.700, t-test p < 0.001).
This table shows molecular features associated with CORO1B in patient tissues and cancer cell lines. In patient samples, CORO1B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
